1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab

US Exec Ivan Cheung Expects ‘More Open Access’ To Drug

 
• By Mandy Jackson

The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab. 

Alzheimer's disease; brain and wooden puzzle on pink background
Eisai will piece together a detailed data package for CMS • Source: Shutterstock

Eisai Co., Ltd. is confident that it has the necessary data to convince the US Centers for Medicare and Medicaid Services to grant broader coverage for its Biogen, Inc.-partnered Alzheimer’s drug candidate lecanemab, if the US Food and Drug Administration approves it next month – setting it up for a potentially much better commercial outlook than the firms’ Aduhelm faced. Many in the Alzheimer's field, impressed with the quality and amount of data presented from the Phase III Clarity AD clinical trial, are optimistic about lecanemab’s chances as well.

The Centers for Medicare and Medicaid Services (CMS) issued a national coverage decision (NCD) providing for coverage with evidence development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from Therapy Areas

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza